ID   MEF2C_MOUSE             Reviewed;         474 AA.
AC   Q8CFN5; Q8R0H1; Q9D7L0; Q9QW20;
DT   04-JAN-2005, integrated into UniProtKB/Swiss-Prot.
DT   04-JAN-2005, sequence version 2.
DT   11-DEC-2019, entry version 164.
DE   RecName: Full=Myocyte-specific enhancer factor 2C {ECO:0000305};
DE   AltName: Full=Myocyte enhancer factor 2C {ECO:0000312|MGI:MGI:99458};
GN   Name=Mef2c {ECO:0000312|MGI:MGI:99458};
OS   Mus musculus (Mouse).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Glires; Rodentia; Myomorpha; Muroidea; Muridae;
OC   Murinae; Mus; Mus.
OX   NCBI_TaxID=10090;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), AND TISSUE SPECIFICITY.
RX   PubMed=8506376; DOI=10.1073/pnas.90.11.5282;
RA   Martin J.F., Schwarz J.J., Olson E.N.;
RT   "Myocyte enhancer factor (MEF) 2C: a tissue-restricted member of the MEF-2
RT   family of transcription factors.";
RL   Proc. Natl. Acad. Sci. U.S.A. 90:5282-5286(1993).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 4).
RC   STRAIN=C57BL/6J; TISSUE=Tongue;
RX   PubMed=16141072; DOI=10.1126/science.1112014;
RA   Carninci P., Kasukawa T., Katayama S., Gough J., Frith M.C., Maeda N.,
RA   Oyama R., Ravasi T., Lenhard B., Wells C., Kodzius R., Shimokawa K.,
RA   Bajic V.B., Brenner S.E., Batalov S., Forrest A.R., Zavolan M., Davis M.J.,
RA   Wilming L.G., Aidinis V., Allen J.E., Ambesi-Impiombato A., Apweiler R.,
RA   Aturaliya R.N., Bailey T.L., Bansal M., Baxter L., Beisel K.W., Bersano T.,
RA   Bono H., Chalk A.M., Chiu K.P., Choudhary V., Christoffels A.,
RA   Clutterbuck D.R., Crowe M.L., Dalla E., Dalrymple B.P., de Bono B.,
RA   Della Gatta G., di Bernardo D., Down T., Engstrom P., Fagiolini M.,
RA   Faulkner G., Fletcher C.F., Fukushima T., Furuno M., Futaki S.,
RA   Gariboldi M., Georgii-Hemming P., Gingeras T.R., Gojobori T., Green R.E.,
RA   Gustincich S., Harbers M., Hayashi Y., Hensch T.K., Hirokawa N., Hill D.,
RA   Huminiecki L., Iacono M., Ikeo K., Iwama A., Ishikawa T., Jakt M.,
RA   Kanapin A., Katoh M., Kawasawa Y., Kelso J., Kitamura H., Kitano H.,
RA   Kollias G., Krishnan S.P., Kruger A., Kummerfeld S.K., Kurochkin I.V.,
RA   Lareau L.F., Lazarevic D., Lipovich L., Liu J., Liuni S., McWilliam S.,
RA   Madan Babu M., Madera M., Marchionni L., Matsuda H., Matsuzawa S., Miki H.,
RA   Mignone F., Miyake S., Morris K., Mottagui-Tabar S., Mulder N., Nakano N.,
RA   Nakauchi H., Ng P., Nilsson R., Nishiguchi S., Nishikawa S., Nori F.,
RA   Ohara O., Okazaki Y., Orlando V., Pang K.C., Pavan W.J., Pavesi G.,
RA   Pesole G., Petrovsky N., Piazza S., Reed J., Reid J.F., Ring B.Z.,
RA   Ringwald M., Rost B., Ruan Y., Salzberg S.L., Sandelin A., Schneider C.,
RA   Schoenbach C., Sekiguchi K., Semple C.A., Seno S., Sessa L., Sheng Y.,
RA   Shibata Y., Shimada H., Shimada K., Silva D., Sinclair B., Sperling S.,
RA   Stupka E., Sugiura K., Sultana R., Takenaka Y., Taki K., Tammoja K.,
RA   Tan S.L., Tang S., Taylor M.S., Tegner J., Teichmann S.A., Ueda H.R.,
RA   van Nimwegen E., Verardo R., Wei C.L., Yagi K., Yamanishi H.,
RA   Zabarovsky E., Zhu S., Zimmer A., Hide W., Bult C., Grimmond S.M.,
RA   Teasdale R.D., Liu E.T., Brusic V., Quackenbush J., Wahlestedt C.,
RA   Mattick J.S., Hume D.A., Kai C., Sasaki D., Tomaru Y., Fukuda S.,
RA   Kanamori-Katayama M., Suzuki M., Aoki J., Arakawa T., Iida J., Imamura K.,
RA   Itoh M., Kato T., Kawaji H., Kawagashira N., Kawashima T., Kojima M.,
RA   Kondo S., Konno H., Nakano K., Ninomiya N., Nishio T., Okada M., Plessy C.,
RA   Shibata K., Shiraki T., Suzuki S., Tagami M., Waki K., Watahiki A.,
RA   Okamura-Oho Y., Suzuki H., Kawai J., Hayashizaki Y.;
RT   "The transcriptional landscape of the mammalian genome.";
RL   Science 309:1559-1563(2005).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 3 AND 5).
RC   TISSUE=Eye;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [4]
RP   TISSUE SPECIFICITY.
RX   PubMed=9013788; DOI=10.1016/s0169-328x(96)00135-0;
RA   Lin X., Shah S., Bulleit R.F.;
RT   "The expression of MEF2 genes is implicated in CNS neuronal
RT   differentiation.";
RL   Brain Res. Mol. Brain Res. 42:307-316(1996).
RN   [5]
RP   PHOSPHORYLATION AT SER-59, AND MUTAGENESIS OF SER-59.
RX   PubMed=8663403; DOI=10.1074/jbc.271.29.17199;
RA   Molkentin J.D., Li L., Olson E.N.;
RT   "Phosphorylation of the MADS-Box transcription factor MEF2C enhances its
RT   DNA binding activity.";
RL   J. Biol. Chem. 271:17199-17204(1996).
RN   [6]
RP   FUNCTION.
RX   PubMed=9162005; DOI=10.1126/science.276.5317.1404;
RA   Lin Q., Schwarz J., Bucana C., Olson E.N.;
RT   "Control of mouse cardiac morphogenesis and myogenesis by transcription
RT   factor MEF2C.";
RL   Science 276:1404-1407(1997).
RN   [7]
RP   FUNCTION, AND DEVELOPMENTAL STAGE.
RX   PubMed=9778514;
RA   Lin Q., Lu J., Yanagisawa H., Webb R., Lyons G.E., Richardson J.A.,
RA   Olson E.N.;
RT   "Requirement of the MADS-box transcription factor MEF2C for vascular
RT   development.";
RL   Development 125:4565-4574(1998).
RN   [8]
RP   FUNCTION, INTERACTION WITH SOX18, AND SUBCELLULAR LOCATION.
RX   PubMed=11554755; DOI=10.1006/bbrc.2001.5589;
RA   Hosking B.M., Wang S.C., Chen S.L., Penning S., Koopman P., Muscat G.E.;
RT   "SOX18 directly interacts with MEF2C in endothelial cells.";
RL   Biochem. Biophys. Res. Commun. 287:493-500(2001).
RN   [9]
RP   INTERACTION WITH HDAC7.
RX   PubMed=11279209; DOI=10.1074/jbc.m101508200;
RA   Dressel U., Bailey P.J., Wang S.-C.M., Downes M., Evans R.M.,
RA   Muscat G.E.O.;
RT   "A dynamic role for HDAC7 in MEF2-mediated muscle differentiation.";
RL   J. Biol. Chem. 276:17007-17013(2001).
RN   [10]
RP   INTERACTION WITH CARM1.
RX   PubMed=11713257; DOI=10.1074/jbc.m109835200;
RA   Chen S.L., Loffler K.A., Chen D., Stallcup M.R., Muscat G.E.;
RT   "The coactivator-associated arginine methyltransferase is necessary for
RT   muscle differentiation: CARM1 coactivates myocyte enhancer factor-2.";
RL   J. Biol. Chem. 277:4324-4333(2002).
RN   [11]
RP   TISSUE SPECIFICITY OF ISOFORMS.
RX   PubMed=15340086; DOI=10.1128/mcb.24.18.8264-8275.2004;
RA   Zhu B., Gulick T.;
RT   "Phosphorylation and alternative pre-mRNA splicing converge to regulate
RT   myocyte enhancer factor 2C activity.";
RL   Mol. Cell. Biol. 24:8264-8275(2004).
RN   [12]
RP   TISSUE SPECIFICITY OF ISOFORMS.
RX   PubMed=15834131; DOI=10.1074/jbc.m502491200;
RA   Zhu B., Ramachandran B., Gulick T.;
RT   "Alternative pre-mRNA splicing governs expression of a conserved acidic
RT   transactivation domain in myocyte enhancer factor 2 factors of striated
RT   muscle and brain.";
RL   J. Biol. Chem. 280:28749-28760(2005).
RN   [13]
RP   INTERACTION WITH MYOCD.
RX   PubMed=16818234; DOI=10.1016/j.molcel.2006.05.026;
RA   Creemers E.E., Sutherland L.B., Oh J., Barbosa A.C., Olson E.N.;
RT   "Coactivation of MEF2 by the SAP domain proteins myocardin and MASTR.";
RL   Mol. Cell 23:83-96(2006).
RN   [14]
RP   FUNCTION, AND TISSUE SPECIFICITY.
RX   PubMed=18438409; DOI=10.1038/ni.1609;
RA   Wilker P.R., Kohyama M., Sandau M.M., Albring J.C., Nakagawa O.,
RA   Schwarz J.J., Murphy K.M.;
RT   "Transcription factor Mef2c is required for B cell proliferation and
RT   survival after antigen receptor stimulation.";
RL   Nat. Immunol. 9:603-612(2008).
RN   [15]
RP   ACETYLATION AT LYS-4, DNA-BINDING, IDENTIFICATION BY MASS SPECTROMETRY,
RP   FUNCTION, AND MUTAGENESIS OF ARG-3 AND LYS-4.
RX   PubMed=18086704; DOI=10.1093/nar/gkm1114;
RA   Angelelli C., Magli A., Ferrari D., Ganassi M., Matafora V., Parise F.,
RA   Razzini G., Bachi A., Ferrari S., Molinari S.;
RT   "Differentiation-dependent lysine 4 acetylation enhances MEF2C binding to
RT   DNA in skeletal muscle cells.";
RL   Nucleic Acids Res. 36:915-928(2008).
RN   [16]
RP   FUNCTION, DISRUPTION PHENOTYPE, AND TISSUE SPECIFICITY.
RX   PubMed=18599438; DOI=10.1073/pnas.0802679105;
RA   Barbosa A.C., Kim M.S., Ertunc M., Adachi M., Nelson E.D., McAnally J.,
RA   Richardson J.A., Kavalali E.T., Monteggia L.M., Bassel-Duby R., Olson E.N.;
RT   "MEF2C, a transcription factor that facilitates learning and memory by
RT   negative regulation of synapse numbers and function.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:9391-9396(2008).
RN   [17]
RP   FUNCTION, AND DISRUPTION PHENOTYPE.
RX   PubMed=18599437; DOI=10.1073/pnas.0802876105;
RA   Li H., Radford J.C., Ragusa M.J., Shea K.L., McKercher S.R., Zaremba J.D.,
RA   Soussou W., Nie Z., Kang Y.J., Nakanishi N., Okamoto S., Roberts A.J.,
RA   Schwarz J.J., Lipton S.A.;
RT   "Transcription factor MEF2C influences neural stem/progenitor cell
RT   differentiation and maturation in vivo.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:9397-9402(2008).
RN   [18]
RP   FUNCTION, AND DISRUPTION PHENOTYPE.
RX   PubMed=19211936; DOI=10.1182/blood-2008-07-167577;
RA   Gekas C., Rhodes K.E., Gereige L.M., Helgadottir H., Ferrari R.,
RA   Kurdistani S.K., Montecino-Rodriguez E., Bassel-Duby R., Olson E.,
RA   Krivtsov A.V., Armstrong S., Orkin S.H., Pellegrini M., Mikkola H.K.;
RT   "Mef2C is a lineage-restricted target of Scl/Tal1 and regulates
RT   megakaryopoiesis and B-cell homeostasis.";
RL   Blood 113:3461-3471(2009).
RN   [19]
RP   INTERACTION WITH LIPN1.
RX   PubMed=19753306; DOI=10.1371/journal.pone.0007031;
RA   Liu G.H., Gerace L.;
RT   "Sumoylation regulates nuclear localization of lipin-1alpha in neuronal
RT   cells.";
RL   PLoS ONE 4:E7031-E7031(2009).
RN   [20]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-98; SER-106; SER-110; SER-222
RP   AND SER-240, PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-108 (ISOFORMS 4
RP   AND 5), AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Brain, Brown adipose tissue, Heart, Kidney, Lung, and Spleen;
RX   PubMed=21183079; DOI=10.1016/j.cell.2010.12.001;
RA   Huttlin E.L., Jedrychowski M.P., Elias J.E., Goswami T., Rad R.,
RA   Beausoleil S.A., Villen J., Haas W., Sowa M.E., Gygi S.P.;
RT   "A tissue-specific atlas of mouse protein phosphorylation and expression.";
RL   Cell 143:1174-1189(2010).
RN   [21]
RP   INTERACTION WITH AKAP13.
RX   PubMed=20139090; DOI=10.1074/jbc.m110.106856;
RA   Mayers C.M., Wadell J., McLean K., Venere M., Malik M., Shibata T.,
RA   Driggers P.H., Kino T., Guo X.C., Koide H., Gorivodsky M., Grinberg A.,
RA   Mukhopadhyay M., Abu-Asab M., Westphal H., Segars J.H.;
RT   "The Rho guanine nucleotide exchange factor AKAP13 (BRX) is essential for
RT   cardiac development in mice.";
RL   J. Biol. Chem. 285:12344-12354(2010).
RN   [22]
RP   INTERACTION WITH FOXK1.
RX   PubMed=22956541; DOI=10.1242/jcs.105239;
RA   Shi X., Wallis A.M., Gerard R.D., Voelker K.A., Grange R.W., DePinho R.A.,
RA   Garry M.G., Garry D.J.;
RT   "Foxk1 promotes cell proliferation and represses myogenic differentiation
RT   by regulating Foxo4 and Mef2.";
RL   J. Cell Sci. 125:5329-5337(2012).
RN   [23]
RP   INTERACTION WITH JPH2.
RX   PubMed=30409805; DOI=10.1126/science.aan3303;
RA   Guo A., Wang Y., Chen B., Wang Y., Yuan J., Zhang L., Hall D., Wu J.,
RA   Shi Y., Zhu Q., Chen C., Thiel W.H., Zhan X., Weiss R.M., Zhan F.,
RA   Musselman C.A., Pufall M., Zhu W., Au K.F., Hong J., Anderson M.E.,
RA   Grueter C.E., Song L.S.;
RT   "E-C coupling structural protein junctophilin-2 encodes a stress-adaptive
RT   transcription regulator.";
RL   Science 0:0-0(2018).
CC   -!- FUNCTION: Transcription activator which binds specifically to the MEF2
CC       element present in the regulatory regions of many muscle-specific
CC       genes. Controls cardiac morphogenesis and myogenesis, and is also
CC       involved in vascular development. Enhances transcriptional activation
CC       mediated by SOX18 (PubMed:11554755). May also be involved in
CC       neurogenesis and in the development of cortical architecture. Isoforms
CC       that lack the repressor domain are more active than isoform 1 (By
CC       similarity). Plays an essential role in hippocampal-dependent learning
CC       and memory by suppressing the number of excitatory synapses and thus
CC       regulating basal and evoked synaptic transmission. Crucial for normal
CC       neuronal development, distribution, and electrical activity in the
CC       neocortex. Necessary for proper development of megakaryocytes and
CC       platelets and for bone marrow B-lymphopoiesis. Required for B-cell
CC       survival and proliferation in response to BCR stimulation, efficient
CC       IgG1 antibody responses to T-cell-dependent antigens and for normal
CC       induction of germinal center B-cells. {ECO:0000250|UniProtKB:Q06413,
CC       ECO:0000269|PubMed:11554755, ECO:0000269|PubMed:18086704,
CC       ECO:0000269|PubMed:18438409, ECO:0000269|PubMed:18599437,
CC       ECO:0000269|PubMed:18599438, ECO:0000269|PubMed:19211936,
CC       ECO:0000269|PubMed:9162005, ECO:0000269|PubMed:9778514}.
CC   -!- SUBUNIT: Forms a complex with class II HDACs in undifferentiating
CC       cells. On myogenic differentiation, HDACs are released into the
CC       cytoplasm allowing MEF2s to interact with other proteins for
CC       activation. Interacts with EP300 in differentiating cells; the
CC       interaction acetylates MEF2C leading to increased DNA binding and
CC       activation (By similarity). Interacts with HDAC7 and CARM1
CC       (PubMed:11279209, PubMed:11713257). Interacts with HDAC4, HDAC7 AND
CC       HDAC9; the interaction with HDACs represses transcriptional activity
CC       (By similarity). Interacts with LPIN1 (PubMed:19753306). Interacts with
CC       MYOCD (PubMed:16818234). Interacts with AKAP13 (PubMed:20139090).
CC       Interacts with FOXK1; the interaction inhibits MEF2C transactivation
CC       activity (PubMed:22956541). Interacts (via N-terminus) with HABP4; this
CC       interaction decreases DNA-binding activity of MEF2C in myocardial cells
CC       in response to mechanical stress (By similarity). Interacts with JPH2;
CC       interaction specifically takes place with the Junctophilin-2 N-terminal
CC       fragment cleavage product of JPH2 (PubMed:30409805). Interacts (via
CC       MADS box) with SOX18 (PubMed:11554755).
CC       {ECO:0000250|UniProtKB:A0A096MJY4, ECO:0000250|UniProtKB:Q06413,
CC       ECO:0000269|PubMed:11279209, ECO:0000269|PubMed:11554755,
CC       ECO:0000269|PubMed:11713257, ECO:0000269|PubMed:16818234,
CC       ECO:0000269|PubMed:19753306, ECO:0000269|PubMed:20139090,
CC       ECO:0000269|PubMed:22956541, ECO:0000269|PubMed:30409805}.
CC   -!- INTERACTION:
CC       Q91V92:Acly; NbExp=3; IntAct=EBI-643822, EBI-644049;
CC       Q8WUI4:HDAC7 (xeno); NbExp=2; IntAct=EBI-643797, EBI-1048378;
CC       Q9QZR5:Hipk2; NbExp=5; IntAct=EBI-643797, EBI-366905;
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:11554755}. Cytoplasm,
CC       sarcoplasm {ECO:0000250|UniProtKB:A0A096MJY4}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=5;
CC         Comment=Additional isoforms seem to exist.;
CC       Name=1;
CC         IsoId=Q8CFN5-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q8CFN5-2; Sequence=VSP_012504;
CC       Name=3;
CC         IsoId=Q8CFN5-3; Sequence=VSP_012505;
CC       Name=4;
CC         IsoId=Q8CFN5-4; Sequence=VSP_012501, VSP_012502, VSP_012503,
CC                                  VSP_012504, VSP_012505;
CC       Name=5;
CC         IsoId=Q8CFN5-5; Sequence=VSP_012501, VSP_012502, VSP_012503;
CC   -!- TISSUE SPECIFICITY: Widely expressed though mainly restricted to
CC       skeletal and cardiac muscle, brain, neurons and lymphocytes. Beta
CC       domain-lacking isoforms are the most predominantly expressed in all
CC       tissues including skeletal and cardiac muscle and brain. Only brain
CC       expresses all isoforms. Expression occurs primarily in the internal
CC       granule cell layer of the olfactory bulb, cortex, thalamus, hippocampus
CC       and cerebellum. Low levels in the cerebellum and hindbrain. Expressed
CC       throughout the cortex, including the frontal and entorhinal cortex,
CC       dentate gyrus, and basolateral amygdala. Selectively expressed in B-
CC       cells but not in T-cells, and its expression increases as B-cells
CC       mature. {ECO:0000269|PubMed:15340086, ECO:0000269|PubMed:15834131,
CC       ECO:0000269|PubMed:18438409, ECO:0000269|PubMed:18599438,
CC       ECO:0000269|PubMed:8506376, ECO:0000269|PubMed:9013788}.
CC   -!- DEVELOPMENTAL STAGE: Expressed in developing endothelial cells and
CC       smooth muscle cells, as well as in surrounding mesenchyme, during
CC       embryogenesis. Up-regulated during myogenesis.
CC       {ECO:0000269|PubMed:9778514}.
CC   -!- DOMAIN: The beta domain, missing in a number of isoforms, is required
CC       for enhancement of transcriptional activity. {ECO:0000250}.
CC   -!- PTM: Phosphorylation on Ser-59 enhances DNA binding activity (By
CC       similarity). Phosphorylation on Ser-396 is required for Lys-391
CC       sumoylation and inhibits transcriptional activity. {ECO:0000250,
CC       ECO:0000269|PubMed:8663403}.
CC   -!- PTM: Acetylated by p300 on several sites in diffentiating myocytes (By
CC       similarity). Acetylation on Lys-4 increases DNA binding and
CC       transactivation. {ECO:0000250, ECO:0000269|PubMed:18086704}.
CC   -!- PTM: Sumoylated on Lys-391 with SUMO2 but not by SUMO1 represses
CC       transcriptional activity. {ECO:0000250}.
CC   -!- PTM: Proteolytically cleaved in cerebellar granule neurons, probably by
CC       caspase 7, following neurotoxicity. Preferentially cleaves the CDK5-
CC       mediated hyperphosphorylated form which leads to neuron apoptosis and
CC       transcriptional inactivation (By similarity). {ECO:0000250}.
CC   -!- DISRUPTION PHENOTYPE: Mice show impairment in hippocampal-dependent
CC       learning and also increase in the number of excitatory synapses and
CC       potentiation of basal and evoked synaptic transmission. Mice surviving
CC       to adulthood manifest smaller, apparently less mature neurons and
CC       smaller whole brain size, with resultant aberrant electrophysiology and
CC       behavior. Mice exhibit thrombocytopenia and a defect in B-
CC       lymphopoiesis. {ECO:0000269|PubMed:18599437,
CC       ECO:0000269|PubMed:18599438, ECO:0000269|PubMed:19211936}.
CC   -!- SIMILARITY: Belongs to the MEF2 family. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AK009139; BAB26099.1; -; mRNA.
DR   EMBL; BC026841; AAH26841.1; -; mRNA.
DR   EMBL; BC037731; AAH37731.1; -; mRNA.
DR   EMBL; BC057650; AAH57650.1; -; mRNA.
DR   CCDS; CCDS26664.1; -. [Q8CFN5-4]
DR   CCDS; CCDS49320.1; -. [Q8CFN5-2]
DR   CCDS; CCDS84042.1; -. [Q8CFN5-1]
DR   CCDS; CCDS84043.1; -. [Q8CFN5-3]
DR   CCDS; CCDS84045.1; -. [Q8CFN5-5]
DR   RefSeq; NP_001334493.1; NM_001347564.1. [Q8CFN5-1]
DR   RefSeq; NP_001334495.1; NM_001347566.1. [Q8CFN5-1]
DR   RefSeq; NP_001334496.1; NM_001347567.1. [Q8CFN5-1]
DR   RefSeq; NP_001334497.1; NM_001347568.1. [Q8CFN5-5]
DR   RefSeq; NP_001334498.1; NM_001347569.1. [Q8CFN5-5]
DR   RefSeq; NP_001334500.1; NM_001347571.1. [Q8CFN5-3]
DR   RefSeq; NP_001334501.1; NM_001347572.1. [Q8CFN5-3]
DR   RefSeq; NP_001334502.1; NM_001347573.1. [Q8CFN5-3]
DR   RefSeq; NP_001334503.1; NM_001347574.1. [Q8CFN5-3]
DR   RefSeq; NP_001334504.1; NM_001347575.1. [Q8CFN5-3]
DR   RefSeq; NP_001334505.1; NM_001347576.1. [Q8CFN5-3]
DR   RefSeq; NP_001334506.1; NM_001347577.1. [Q8CFN5-3]
DR   RefSeq; NP_079558.1; NM_025282.3. [Q8CFN5-4]
DR   RefSeq; XP_006517186.1; XM_006517123.2. [Q8CFN5-1]
DR   RefSeq; XP_006517187.1; XM_006517124.3. [Q8CFN5-1]
DR   RefSeq; XP_006517189.1; XM_006517126.2. [Q8CFN5-5]
DR   RefSeq; XP_006517195.1; XM_006517132.3. [Q8CFN5-4]
DR   RefSeq; XP_011242794.1; XM_011244492.2. [Q8CFN5-1]
DR   RefSeq; XP_017170894.1; XM_017315405.1. [Q8CFN5-1]
DR   PDB; 5F28; X-ray; 2.90 A; A/B/C/D=1-95.
DR   PDBsum; 5F28; -.
DR   SMR; Q8CFN5; -.
DR   BioGrid; 201383; 12.
DR   DIP; DIP-49524N; -.
DR   ELM; Q8CFN5; -.
DR   IntAct; Q8CFN5; 8.
DR   MINT; Q8CFN5; -.
DR   STRING; 10090.ENSMUSP00000132547; -.
DR   iPTMnet; Q8CFN5; -.
DR   PhosphoSitePlus; Q8CFN5; -.
DR   PaxDb; Q8CFN5; -.
DR   PeptideAtlas; Q8CFN5; -.
DR   PRIDE; Q8CFN5; -.
DR   Ensembl; ENSMUST00000185052; ENSMUSP00000138826; ENSMUSG00000005583. [Q8CFN5-5]
DR   Ensembl; ENSMUST00000197146; ENSMUSP00000143227; ENSMUSG00000005583. [Q8CFN5-3]
DR   Ensembl; ENSMUST00000197681; ENSMUSP00000143420; ENSMUSG00000005583. [Q8CFN5-3]
DR   Ensembl; ENSMUST00000198199; ENSMUSP00000143742; ENSMUSG00000005583. [Q8CFN5-4]
DR   Ensembl; ENSMUST00000199019; ENSMUSP00000143401; ENSMUSG00000005583. [Q8CFN5-1]
DR   Ensembl; ENSMUST00000199105; ENSMUSP00000143212; ENSMUSG00000005583. [Q8CFN5-1]
DR   Ensembl; ENSMUST00000199450; ENSMUSP00000143315; ENSMUSG00000005583. [Q8CFN5-2]
DR   GeneID; 17260; -.
DR   KEGG; mmu:17260; -.
DR   UCSC; uc007rie.2; mouse. [Q8CFN5-4]
DR   UCSC; uc007rih.2; mouse. [Q8CFN5-5]
DR   UCSC; uc007rii.3; mouse. [Q8CFN5-3]
DR   CTD; 4208; -.
DR   MGI; MGI:99458; Mef2c.
DR   eggNOG; KOG0014; Eukaryota.
DR   eggNOG; COG5068; LUCA.
DR   GeneTree; ENSGT00940000157492; -.
DR   HOGENOM; HOG000230620; -.
DR   InParanoid; Q8CFN5; -.
DR   KO; K04454; -.
DR   OrthoDB; 729387at2759; -.
DR   PhylomeDB; Q8CFN5; -.
DR   TreeFam; TF314067; -.
DR   Reactome; R-MMU-525793; Myogenesis.
DR   ChiTaRS; Mef2c; mouse.
DR   PRO; PR:Q8CFN5; -.
DR   Proteomes; UP000000589; Chromosome 13.
DR   RNAct; Q8CFN5; protein.
DR   Bgee; ENSMUSG00000005583; Expressed in 351 organ(s), highest expression level in cerebral cortex.
DR   ExpressionAtlas; Q8CFN5; baseline and differential.
DR   Genevisible; Q8CFN5; MM.
DR   GO; GO:0005737; C:cytoplasm; ISS:UniProtKB.
DR   GO; GO:0005829; C:cytosol; ISS:Alzheimers_University_of_Toronto.
DR   GO; GO:0043231; C:intracellular membrane-bounded organelle; ISO:MGI.
DR   GO; GO:0000790; C:nuclear chromatin; IBA:GO_Central.
DR   GO; GO:0016607; C:nuclear speck; ISS:UniProtKB.
DR   GO; GO:0005654; C:nucleoplasm; ISO:MGI.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0098794; C:postsynapse; IEA:GOC.
DR   GO; GO:0032991; C:protein-containing complex; ISS:UniProtKB.
DR   GO; GO:0030017; C:sarcomere; ISO:MGI.
DR   GO; GO:0016528; C:sarcoplasm; IEA:UniProtKB-SubCell.
DR   GO; GO:0033613; F:activating transcription factor binding; ISO:MGI.
DR   GO; GO:0003680; F:AT DNA binding; ISO:MGI.
DR   GO; GO:0003682; F:chromatin binding; IDA:MGI.
DR   GO; GO:0003677; F:DNA binding; IDA:MGI.
DR   GO; GO:0001228; F:DNA-binding transcription activator activity, RNA polymerase II-specific; IDA:NTNU_SB.
DR   GO; GO:0003700; F:DNA-binding transcription factor activity; IDA:MGI.
DR   GO; GO:0000981; F:DNA-binding transcription factor activity, RNA polymerase II-specific; IDA:UniProtKB.
DR   GO; GO:0042826; F:histone deacetylase binding; IPI:BHF-UCL.
DR   GO; GO:0071837; F:HMG box domain binding; IPI:UniProtKB.
DR   GO; GO:0046982; F:protein heterodimerization activity; ISO:MGI.
DR   GO; GO:0000987; F:proximal promoter sequence-specific DNA binding; IDA:MGI.
DR   GO; GO:0000978; F:RNA polymerase II cis-regulatory region sequence-specific DNA binding; IDA:UniProtKB.
DR   GO; GO:0000977; F:RNA polymerase II regulatory region sequence-specific DNA binding; IDA:UniProtKB.
DR   GO; GO:0043565; F:sequence-specific DNA binding; IDA:UniProtKB.
DR   GO; GO:0008134; F:transcription factor binding; IBA:GO_Central.
DR   GO; GO:0044212; F:transcription regulatory region DNA binding; IDA:BHF-UCL.
DR   GO; GO:0006915; P:apoptotic process; IEA:UniProtKB-KW.
DR   GO; GO:0001782; P:B cell homeostasis; IMP:UniProtKB.
DR   GO; GO:0042100; P:B cell proliferation; IMP:UniProtKB.
DR   GO; GO:0050853; P:B cell receptor signaling pathway; IMP:UniProtKB.
DR   GO; GO:0001568; P:blood vessel development; IMP:MGI.
DR   GO; GO:0001974; P:blood vessel remodeling; IMP:MGI.
DR   GO; GO:0055007; P:cardiac muscle cell differentiation; IGI:MGI.
DR   GO; GO:0014898; P:cardiac muscle hypertrophy in response to stress; IMP:MGI.
DR   GO; GO:0003211; P:cardiac ventricle formation; IMP:UniProtKB.
DR   GO; GO:0060536; P:cartilage morphogenesis; IMP:MGI.
DR   GO; GO:0045165; P:cell fate commitment; IMP:MGI.
DR   GO; GO:0048667; P:cell morphogenesis involved in neuron differentiation; IMP:Alzheimers_University_of_Toronto.
DR   GO; GO:0071277; P:cellular response to calcium ion; IDA:UniProtKB.
DR   GO; GO:0035690; P:cellular response to drug; IDA:UniProtKB.
DR   GO; GO:0071498; P:cellular response to fluid shear stress; IDA:UniProtKB.
DR   GO; GO:0071363; P:cellular response to growth factor stimulus; ISO:MGI.
DR   GO; GO:0071222; P:cellular response to lipopolysaccharide; IDA:UniProtKB.
DR   GO; GO:0071374; P:cellular response to parathyroid hormone stimulus; ISS:UniProtKB.
DR   GO; GO:0071300; P:cellular response to retinoic acid; ISO:MGI.
DR   GO; GO:0071560; P:cellular response to transforming growth factor beta stimulus; ISS:UniProtKB.
DR   GO; GO:0035984; P:cellular response to trichostatin A; IDA:UniProtKB.
DR   GO; GO:0002062; P:chondrocyte differentiation; IGI:MGI.
DR   GO; GO:0048704; P:embryonic skeletal system morphogenesis; IMP:MGI.
DR   GO; GO:0048703; P:embryonic viscerocranium morphogenesis; IMP:MGI.
DR   GO; GO:0001958; P:endochondral ossification; IMP:MGI.
DR   GO; GO:2001013; P:epithelial cell proliferation involved in renal tubule morphogenesis; IMP:UniProtKB.
DR   GO; GO:0060079; P:excitatory postsynaptic potential; IMP:Alzheimers_University_of_Toronto.
DR   GO; GO:0002467; P:germinal center formation; IMP:UniProtKB.
DR   GO; GO:0072102; P:glomerulus morphogenesis; IMP:UniProtKB.
DR   GO; GO:0007507; P:heart development; IMP:MGI.
DR   GO; GO:0001947; P:heart looping; IMP:UniProtKB.
DR   GO; GO:0006959; P:humoral immune response; IMP:UniProtKB.
DR   GO; GO:0007611; P:learning or memory; IMP:UniProtKB.
DR   GO; GO:0000165; P:MAPK cascade; IDA:UniProtKB.
DR   GO; GO:0030318; P:melanocyte differentiation; IMP:UniProtKB.
DR   GO; GO:0030224; P:monocyte differentiation; IMP:MGI.
DR   GO; GO:0007275; P:multicellular organism development; IBA:GO_Central.
DR   GO; GO:0007521; P:muscle cell fate determination; IMP:MGI.
DR   GO; GO:0014902; P:myotube differentiation; IEA:Ensembl.
DR   GO; GO:0043537; P:negative regulation of blood vessel endothelial cell migration; ISO:MGI.
DR   GO; GO:0050680; P:negative regulation of epithelial cell proliferation; IMP:UniProtKB.
DR   GO; GO:0010629; P:negative regulation of gene expression; IMP:UniProtKB.
DR   GO; GO:0043524; P:negative regulation of neuron apoptotic process; IDA:UniProtKB.
DR   GO; GO:0030279; P:negative regulation of ossification; ISS:UniProtKB.
DR   GO; GO:0000122; P:negative regulation of transcription by RNA polymerase II; IGI:MGI.
DR   GO; GO:1904753; P:negative regulation of vascular associated smooth muscle cell migration; ISO:MGI.
DR   GO; GO:1905563; P:negative regulation of vascular endothelial cell proliferation; ISO:MGI.
DR   GO; GO:1904706; P:negative regulation of vascular smooth muscle cell proliferation; ISO:MGI.
DR   GO; GO:0072160; P:nephron tubule epithelial cell differentiation; IMP:UniProtKB.
DR   GO; GO:0014033; P:neural crest cell differentiation; IMP:UniProtKB.
DR   GO; GO:0048666; P:neuron development; IMP:UniProtKB.
DR   GO; GO:0030182; P:neuron differentiation; IMP:UniProtKB.
DR   GO; GO:0001764; P:neuron migration; IMP:Alzheimers_University_of_Toronto.
DR   GO; GO:0001649; P:osteoblast differentiation; IGI:MGI.
DR   GO; GO:0003151; P:outflow tract morphogenesis; IGI:MGI.
DR   GO; GO:0030220; P:platelet formation; IMP:UniProtKB.
DR   GO; GO:0010694; P:positive regulation of alkaline phosphatase activity; IMP:UniProtKB.
DR   GO; GO:0030890; P:positive regulation of B cell proliferation; IMP:UniProtKB.
DR   GO; GO:2000987; P:positive regulation of behavioral fear response; IMP:UniProtKB.
DR   GO; GO:0030501; P:positive regulation of bone mineralization; IMP:UniProtKB.
DR   GO; GO:2000727; P:positive regulation of cardiac muscle cell differentiation; IMP:UniProtKB.
DR   GO; GO:0060045; P:positive regulation of cardiac muscle cell proliferation; IMP:UniProtKB.
DR   GO; GO:0010613; P:positive regulation of cardiac muscle hypertrophy; ISO:MGI.
DR   GO; GO:0071864; P:positive regulation of cell proliferation in bone marrow; IGI:MGI.
DR   GO; GO:0010628; P:positive regulation of gene expression; IDA:UniProtKB.
DR   GO; GO:2000111; P:positive regulation of macrophage apoptotic process; IMP:UniProtKB.
DR   GO; GO:0043406; P:positive regulation of MAP kinase activity; ISS:Alzheimers_University_of_Toronto.
DR   GO; GO:0045663; P:positive regulation of myoblast differentiation; ISS:UniProtKB.
DR   GO; GO:0045666; P:positive regulation of neuron differentiation; IDA:UniProtKB.
DR   GO; GO:0045669; P:positive regulation of osteoblast differentiation; IMP:UniProtKB.
DR   GO; GO:2001016; P:positive regulation of skeletal muscle cell differentiation; ISO:MGI.
DR   GO; GO:0048643; P:positive regulation of skeletal muscle tissue development; ISS:UniProtKB.
DR   GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; IDA:NTNU_SB.
DR   GO; GO:0045893; P:positive regulation of transcription, DNA-templated; IDA:UniProtKB.
DR   GO; GO:0003138; P:primary heart field specification; IMP:UniProtKB.
DR   GO; GO:2000311; P:regulation of AMPA receptor activity; IMP:Alzheimers_University_of_Toronto.
DR   GO; GO:0060998; P:regulation of dendritic spine development; IMP:Alzheimers_University_of_Toronto.
DR   GO; GO:0002634; P:regulation of germinal center formation; IMP:UniProtKB.
DR   GO; GO:0045652; P:regulation of megakaryocyte differentiation; IMP:UniProtKB.
DR   GO; GO:0043523; P:regulation of neuron apoptotic process; IMP:Alzheimers_University_of_Toronto.
DR   GO; GO:0046928; P:regulation of neurotransmitter secretion; IMP:Alzheimers_University_of_Toronto.
DR   GO; GO:2000310; P:regulation of NMDA receptor activity; IMP:Alzheimers_University_of_Toronto.
DR   GO; GO:0060297; P:regulation of sarcomere organization; IMP:MGI.
DR   GO; GO:0051963; P:regulation of synapse assembly; IMP:Alzheimers_University_of_Toronto.
DR   GO; GO:0060025; P:regulation of synaptic activity; IMP:UniProtKB.
DR   GO; GO:0048167; P:regulation of synaptic plasticity; IMP:Alzheimers_University_of_Toronto.
DR   GO; GO:0051966; P:regulation of synaptic transmission, glutamatergic; IMP:Alzheimers_University_of_Toronto.
DR   GO; GO:0006355; P:regulation of transcription, DNA-templated; IDA:MGI.
DR   GO; GO:0061333; P:renal tubule morphogenesis; IMP:UniProtKB.
DR   GO; GO:0002931; P:response to ischemia; ISS:Alzheimers_University_of_Toronto.
DR   GO; GO:0060021; P:roof of mouth development; IGI:MGI.
DR   GO; GO:0003139; P:secondary heart field specification; IMP:UniProtKB.
DR   GO; GO:0003185; P:sinoatrial valve morphogenesis; IMP:UniProtKB.
DR   GO; GO:0035914; P:skeletal muscle cell differentiation; IMP:MGI.
DR   GO; GO:0007519; P:skeletal muscle tissue development; IMP:MGI.
DR   GO; GO:0051145; P:smooth muscle cell differentiation; IMP:MGI.
DR   GO; GO:0060290; P:transdifferentiation; ISO:MGI.
DR   GO; GO:0055012; P:ventricular cardiac muscle cell differentiation; IMP:UniProtKB.
DR   CDD; cd00265; MADS_MEF2_like; 1.
DR   Gene3D; 3.40.1810.10; -; 1.
DR   InterPro; IPR022102; HJURP_C.
DR   InterPro; IPR033896; MADS_MEF2-like.
DR   InterPro; IPR002100; TF_MADSbox.
DR   InterPro; IPR036879; TF_MADSbox_sf.
DR   Pfam; PF12347; HJURP_C; 1.
DR   Pfam; PF00319; SRF-TF; 1.
DR   PRINTS; PR00404; MADSDOMAIN.
DR   SMART; SM00432; MADS; 1.
DR   SUPFAM; SSF55455; SSF55455; 1.
DR   PROSITE; PS00350; MADS_BOX_1; 1.
DR   PROSITE; PS50066; MADS_BOX_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Activator; Alternative splicing; Apoptosis;
KW   Cytoplasm; Developmental protein; Differentiation; DNA-binding;
KW   Isopeptide bond; Neurogenesis; Nucleus; Phosphoprotein; Reference proteome;
KW   Transcription; Transcription regulation; Ubl conjugation.
FT   CHAIN           1..474
FT                   /note="Myocyte-specific enhancer factor 2C"
FT                   /id="PRO_0000199434"
FT   DOMAIN          3..57
FT                   /note="MADS-box"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00251"
FT   DNA_BIND        58..86
FT                   /note="Mef2-type"
FT                   /evidence="ECO:0000255"
FT   REGION          271..278
FT                   /note="Beta domain"
FT                   /evidence="ECO:0000250"
FT   REGION          368..399
FT                   /note="Transcription repressor"
FT                   /evidence="ECO:0000250"
FT   COMPBIAS        4..31
FT                   /note="Lys-rich (basic)"
FT   COMPBIAS        146..183
FT                   /note="Ser-rich"
FT   SITE            433..434
FT                   /note="Cleavage"
FT                   /evidence="ECO:0000305"
FT   MOD_RES         4
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000269|PubMed:18086704"
FT   MOD_RES         59
FT                   /note="Phosphoserine; by CK2"
FT                   /evidence="ECO:0000269|PubMed:8663403"
FT   MOD_RES         98
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:21183079"
FT   MOD_RES         106
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:21183079"
FT   MOD_RES         110
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:21183079"
FT   MOD_RES         116
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:Q06413"
FT   MOD_RES         119
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:Q06413"
FT   MOD_RES         222
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:21183079"
FT   MOD_RES         228
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q06413"
FT   MOD_RES         234
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:Q06413"
FT   MOD_RES         239
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:Q06413"
FT   MOD_RES         240
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000244|PubMed:21183079"
FT   MOD_RES         252
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:Q06413"
FT   MOD_RES         264
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:Q06413"
FT   MOD_RES         293
FT                   /note="Phosphothreonine; by MAPK14"
FT                   /evidence="ECO:0000250|UniProtKB:Q06413"
FT   MOD_RES         300
FT                   /note="Phosphothreonine; by MAPK14"
FT                   /evidence="ECO:0000250|UniProtKB:Q06413"
FT   MOD_RES         396
FT                   /note="Phosphoserine; by CDK5"
FT                   /evidence="ECO:0000250|UniProtKB:Q06413"
FT   MOD_RES         420
FT                   /note="Phosphoserine; by MAPK7"
FT                   /evidence="ECO:0000250|UniProtKB:Q06413"
FT   MOD_RES         446
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q06413"
FT   CROSSLNK        391
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO)"
FT                   /evidence="ECO:0000250"
FT   VAR_SEQ         87..97
FT                   /note="TLRKKGLNGCD -> ALNKKENKGSE (in isoform 4 and isoform
FT                   5)"
FT                   /evidence="ECO:0000303|PubMed:15489334,
FT                   ECO:0000303|PubMed:16141072"
FT                   /id="VSP_012501"
FT   VAR_SEQ         103..118
FT                   /note="ADDSVGHSPESEDKYR -> SSYALTPRTEEKYK (in isoform 4 and
FT                   isoform 5)"
FT                   /evidence="ECO:0000303|PubMed:15489334,
FT                   ECO:0000303|PubMed:16141072"
FT                   /id="VSP_012502"
FT   VAR_SEQ         123..134
FT                   /note="DIDLMISRQRLC -> EFDNMIKSHKIP (in isoform 4 and
FT                   isoform 5)"
FT                   /evidence="ECO:0000303|PubMed:15489334,
FT                   ECO:0000303|PubMed:16141072"
FT                   /id="VSP_012503"
FT   VAR_SEQ         271..278
FT                   /note="Missing (in isoform 2 and isoform 4)"
FT                   /evidence="ECO:0000303|PubMed:16141072,
FT                   ECO:0000303|PubMed:8506376"
FT                   /id="VSP_012504"
FT   VAR_SEQ         368..399
FT                   /note="Missing (in isoform 3 and isoform 4)"
FT                   /evidence="ECO:0000303|PubMed:15489334,
FT                   ECO:0000303|PubMed:16141072"
FT                   /id="VSP_012505"
FT   MUTAGEN         3
FT                   /note="R->T: Increased mobility in differentiating cells.
FT                   Greatly reduced DNA binding."
FT                   /evidence="ECO:0000269|PubMed:18086704"
FT   MUTAGEN         4
FT                   /note="K->Q: 7-fold increase in DNA binding."
FT                   /evidence="ECO:0000269|PubMed:18086704"
FT   MUTAGEN         4
FT                   /note="K->R: Reduced acetylation by 30%. Some loss of DNA
FT                   binding and transactivation activity."
FT                   /evidence="ECO:0000269|PubMed:18086704"
FT   MUTAGEN         59..60
FT                   /note="ST->CR: Reduced DNA binding activity."
FT   MUTAGEN         59..60
FT                   /note="ST->DD: Enhanced DNA binding activity."
FT   MUTAGEN         59
FT                   /note="S->A: Reduced DNA binding activity."
FT                   /evidence="ECO:0000269|PubMed:8663403"
FT   MUTAGEN         59
FT                   /note="S->D: Enhanced DNA binding activity."
FT                   /evidence="ECO:0000269|PubMed:8663403"
FT   CONFLICT        141
FT                   /note="F -> L (in Ref. 3; AAH37731)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        211
FT                   /note="S -> P (in Ref. 1)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        428
FT                   /note="C -> S (in Ref. 1)"
FT                   /evidence="ECO:0000305"
FT   HELIX           22..38
FT                   /evidence="ECO:0000244|PDB:5F28"
FT   STRAND          42..48
FT                   /evidence="ECO:0000244|PDB:5F28"
FT   STRAND          54..60
FT                   /evidence="ECO:0000244|PDB:5F28"
FT   HELIX           62..70
FT                   /evidence="ECO:0000244|PDB:5F28"
FT   STRAND          77..79
FT                   /evidence="ECO:0000244|PDB:5F28"
FT   HELIX           81..88
FT                   /evidence="ECO:0000244|PDB:5F28"
FT   MOD_RES         Q8CFN5-4:108
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000244|PubMed:21183079"
FT   MOD_RES         Q8CFN5-5:108
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000244|PubMed:21183079"
SQ   SEQUENCE   474 AA;  51278 MW;  CEFC2DB21E89632A CRC64;
     MGRKKIQITR IMDERNRQVT FTKRKFGLMK KAYELSVLCD CEIALIIFNS TNKLFQYAST
     DMDKVLLKYT EYNEPHESRT NSDIVETLRK KGLNGCDSPD PDADDSVGHS PESEDKYRKI
     NEDIDLMISR QRLCAVPPPS FEMPVTIPVS SHNSLVYSNP VSTLGNPNLL PLAHPSLQRN
     SMSPGVTHRP PSAGNTGGLM GGDLTSGAGT SAGNGYGNPR NSPGLLVSPG NLNKNIQAKS
     PPPMNLGMNN RKPDLRVLIP PGSKNTMPSV SEDVDLLLNQ RINNSQSAQS LATPVVSVAT
     PTLPGQGMGG YPSAISTTYG TEYSLSSADL SSLSGFNTAS ALHLGSVTGW QQQHLHNMPP
     SALSQLGACT STHLSQSSNL SLPSTQSLSI KSEPVSPPRD RTTTPSRYPQ HTTRHEAGRS
     PVDSLSSCSS SYDGSDREDH RNEFHSPIGL TRPSPDERES PSVKRMRLSE GWAT
//
